OncoNano Medicine, Inc.

OncoNano has pioneered an ultra pH-sensitive, polymeric micelle platform technology to selectively deliver high-value small molecule and biologic payloads to a wide range of tumor types for use across the continuum of cancer care: Diagnosis, Staging, Surgery and Treatment. The mechanism of action utilizes the low pH tumor microenvironment (TME; Warburg) as a universal biomarker for solid cancers. An imaging program (ONM-100) is in Ph 2 trials for intraoperative tumor resection, and in Ph 1 trials was well-tolerated, identified 100% of tumors found by standard of care (SOC), and occult disease undetected by SOC in 30% of the patients. The results have validated use of the micelles for therapeutic applications that are in preclinical phase: (i) ON-BOARD™ to selectively deliver micelle-encapsulated small molecules, antibody fragments, and cytokines (e.g. IL-2) to the TME to improve therapeutic indexes, and (ii) OMNI™ for antigen-containing micelles that activate T-cell immune response.